Navitoclax (ABT-263)

Catalog No.S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 38 Publications

13 Customer Reviews

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    Navitoclax (ABT-263) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    Navitoclax (ABT-263) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell M2PhdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml2wTWM2OD1yLkCwOlY6KM7:TR?= NHvxZmhUSU6JRWK=
MV-4-11 NXPLZlNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlv0TWM2OD1yLkCxOVg3KM7:TR?= NYqzeplKW0GQR1XS
NKM-1 NYi2dIlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwMEG2PVkh|ryP MlfuV2FPT0WU
ML-2 NEXzSZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{flNGlEPTB;MD6wNVk5OyEQvF2= NWPS[HlGW0GQR1XS
BV-173 M4j0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInHclNKSzVyPUCuNFI{OTRizszN MnzYV2FPT0WU
RS4-11 MoXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPmT45NUUN3ME2wMlAzPTh5IN88US=> MoD4V2FPT0WU
HL-60 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[zTWM2OD1yLkCyPVA5KM7:TR?= MWPTRW5ITVJ?
KY821 NI\ubZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2C5UmlEPTB;MD6wNlk4PSEQvF2= NEjGOXRUSU6JRWK=
ECC10 M3j6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWG5OIlsUUN3ME2wMlA{Pzl{IN88US=> M1vDZ3NCVkeHUh?=
NCI-H720 NYnaZppoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknuTWM2OD1yLkC0NFEyKM7:TR?= NF\ZbWJUSU6JRWK=
QIMR-WIL M2nLZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMESyPFch|ryP M1\EVnNCVkeHUh?=
KG-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[xZWlEPTB;MD6wOFQ5PiEQvF2= NUHr[WlLW0GQR1XS
TGW MonSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[2NZY1UUN3ME2wMlA1PjN|IN88US=> M3TITXNCVkeHUh?=
ATN-1 MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvmTWM2OD1yLkC0O|M{KM7:TR?= NEPJdIlUSU6JRWK=
RH-18 NV:2[JBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHkc3EyUUN3ME2wMlA3ODR6IN88US=> Mk\rV2FPT0WU
EW-18 NYXVfXdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{P1[2lEPTB;MD6wOlg1OSEQvF2= NGrV[llUSU6JRWK=
NB17 M2fFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTRd|M3UUN3ME2wMlA4OTJ2IN88US=> M3rXbXNCVkeHUh?=
SK-NEP-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPYNFNYUUN3ME2wMlA4OjF|IN88US=> NVrDd2dvW0GQR1XS
P12-ICHIKAWA NGW4U4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nwWmlEPTB;MD6wO|c4QCEQvF2= NGW5UYRUSU6JRWK=
KARPAS-45 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nLVGlEPTB;MD6wO|gyPSEQvF2= MX7TRW5ITVJ?
EW-3 NVjTTW5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MliwTWM2OD1yLkC4NFU{KM7:TR?= MWrTRW5ITVJ?
NB13 M4XkPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrQTWM2OD1yLkC4NlA{KM7:TR?= NFe3[3VUSU6JRWK=
NCI-H209 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVf5d3pOUUN3ME2wMlA5PzB2IN88US=> NG\V[YZUSU6JRWK=
NCI-H1092 M1nuV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEO3[HRKSzVyPUCuNVAzPzVizszN NYjV[ZEyW0GQR1XS
NH-12 NGnZdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwMUC3OFQh|ryP NIXS[3ZUSU6JRWK=
697 NV3WUo9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\NSGlEPTB;MD6xNFg{QSEQvF2= M{T3OXNCVkeHUh?=
KE-37 M1S1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknyTWM2OD1yLkGxN|ch|ryP NH7XdI5USU6JRWK=
MOLT-4 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfDXmhKSzVyPUCuNVUyPjlizszN MWnTRW5ITVJ?
CHP-134 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Pu[2lEPTB;MD6xOlMxPiEQvF2= NELVPXBUSU6JRWK=
D-283MED NXfIOnZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInhNZVKSzVyPUCuNVc3QDZizszN M{j4TXNCVkeHUh?=
LU-135 M1\ycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LFdWlEPTB;MD6xPFU2OiEQvF2= M3Hte3NCVkeHUh?=
LU-134-A M1;2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHrTWM2OD1yLkG4OlcyKM7:TR?= NIra[W5USU6JRWK=
EM-2 NYXv[5dDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rQTGlEPTB;MD6xPVkyQCEQvF2= M2O0dHNCVkeHUh?=
LU-139 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LoSGlEPTB;MD6yNFQ6QCEQvF2= NE[4OGFUSU6JRWK=
ALL-PO M{fo[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3qZ3BKSzVyPUCuNlE6QDhizszN MY\TRW5ITVJ?
NB12 MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDHc3pKSzVyPUCuNlMyOTVizszN MlTBV2FPT0WU
KP-N-YN MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4H5bmlEPTB;MD6yN|U4OyEQvF2= MUfTRW5ITVJ?
BEN NX3xTY9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwMkO5Olgh|ryP MXrTRW5ITVJ?
HCC1569 NITGSYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvrS2NKSzVyPUCuNlUyODZizszN Mkm4V2FPT0WU
HuO9 NEHsb2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPVNmw1UUN3ME2wMlI3PzF3IN88US=> NVX0RWpYW0GQR1XS
WM-115 NVrYPZNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnZRoFKSzVyPUCuNlc4OzhizszN MVjTRW5ITVJ?
CCRF-CEM MkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwM{O1Nlkh|ryP M1TxOHNCVkeHUh?=
IST-SL1 NWHWTHluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwM{WzOFMh|ryP NGjoT|FUSU6JRWK=
BE-13 NVnPOnFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XzdmlEPTB;MD6zOlQ2QSEQvF2= M1\5VXNCVkeHUh?=
COR-L88 MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vCV2lEPTB;MD6zOlU1KM7:TR?= MXXTRW5ITVJ?
DOHH-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwNEGwNlMh|ryP MnXiV2FPT0WU
A704 NFP4R5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwNEK2O{DPxE1? M4f4e3NCVkeHUh?=
KNS-81-FD NYPPbWl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjLUXRKSzVyPUCuOFQxOTdizszN NWDXS5puW0GQR1XS
RPMI-8226 NXzHWJoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXmxTndSUUN3ME2wMlQ2PjV{IN88US=> NGDPclZUSU6JRWK=
TGBC24TKB NX\hUoZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwNEW3O|gh|ryP NIXGcpZUSU6JRWK=
NCI-H1304 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGH4R3hKSzVyPUCuOFYyPTdizszN M{PHOHNCVkeHUh?=
MOLT-13 NEDKRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwNE[2NVMh|ryP NV;BWFVYW0GQR1XS
EW-22 NF\6eHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jxVGlEPTB;MD60OlY4OSEQvF2= NUjWR4JzW0GQR1XS
MS-1 MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwNE[5N|Mh|ryP MlvMV2FPT0WU
RMG-I MmDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXETWM2OD1yLkS5OFY1KM7:TR?= Moi5V2FPT0WU
NTERA-S-cl-D1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1q1R2lEPTB;MD61NFAyQSEQvF2= NV7TUI8zW0GQR1XS
NCI-H1048 NGLIVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwNUC5OVMh|ryP NWH5[2ZIW0GQR1XS
SW1417 MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwNUW0N|gh|ryP M4LaeXNCVkeHUh?=
DB NHTreoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXGwc4R[UUN3ME2wMlU4ODhizszN MXLTRW5ITVJ?
MEG-01 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwNUizNkDPxE1? M2HHSnNCVkeHUh?=
EW-13 NWrnd|JVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfaWldQUUN3ME2wMlU5OzRzIN88US=> Mo\NV2FPT0WU
LAMA-84 Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIj5SmxKSzVyPUCuOVkzODdizszN NFrmPJBUSU6JRWK=
J-RT3-T3-5 MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwNkC4NFgh|ryP M1TzbnNCVkeHUh?=
MOLT-16 M17pOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[0XmlEPTB;MD62OVI3PCEQvF2= NUnYPY5vW0GQR1XS
DU-4475 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzmTWM2OD1yLk[1OFI4KM7:TR?= M4LGSHNCVkeHUh?=
HAL-01 NH\pfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\xTWM2OD1yLkeyOVQ6KM7:TR?= NGjDU25USU6JRWK=
RD M3TaUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTtRmRRUUN3ME2wMlc2QDl7IN88US=> NX7aWmt3W0GQR1XS
OAW-28 MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwN{izO{DPxE1? M4fzZ3NCVkeHUh?=
HCC38 NFvmbWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HTXmlEPTB;MD64NFE6KM7:TR?= M1zyfXNCVkeHUh?=
NMC-G1 MmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7hc2lKSzVyPUCuPFEyOjFizszN Ml7tV2FPT0WU
EW-16 Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHnTWM2OD1yLkixN|I5KM7:TR?= Ml7ZV2FPT0WU
DU-145 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzqTWM2OD1yLki5PVI{KM7:TR?= MX3TRW5ITVJ?
HPAF-II M1jBbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwOUK2Nlgh|ryP MXzTRW5ITVJ?
A427 NGX1cYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7vS|VtUUN3ME2wMlk{ODJ{IN88US=> MlrFV2FPT0WU
PA-1 NXHhVFJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwOUW2OFIh|ryP NVfjdlFIW0GQR1XS
OAW-42 NYD5S2E2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfqTWM2OD1yLkm2NVQ3KM7:TR?= MY\TRW5ITVJ?
L-428 M1;yWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTFwMEGyOUDPxE1? MYXTRW5ITVJ?
COLO-824 MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTFwMEG3NFgh|ryP Mmq1V2FPT0WU
P30-OHK M4rLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\GVGlEPTB;MT6wOFY5QCEQvF2= NF\1XVlUSU6JRWK=
NCI-H2170 NYjKXZkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\Ce2lEPTB;MT6wOlI{KM7:TR?= NFHOWWtUSU6JRWK=
HCC2998 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTFwMEexN|Uh|ryP NILBRZpUSU6JRWK=
NB14 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTsXJF{UUN3ME2xMlE{PzR6IN88US=> NXz6eHpwW0GQR1XS
TGBC1TKB NWfIeHg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofrTWM2OD1zLkG0NVUzKM7:TR?= NWXSd2ozW0GQR1XS
KP-N-YS MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlX0TWM2OD1zLkG2NlM3KM7:TR?= M2TDcXNCVkeHUh?=
CAL-120 M2T5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TzXGlEPTB;MT6xOlQzQSEQvF2= Mm[4V2FPT0WU
SBC-1 NFHNN2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTFwMUmwOVMh|ryP Ml\sV2FPT0WU
C32 NH22VGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPxZXNWUUN3ME2xMlE6ODh6IN88US=> MVTTRW5ITVJ?
HCC2157 M4H3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTFwMUm0PVQh|ryP NX\sWGdoW0GQR1XS
COLO-792 NEK4UG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVWySoVLUUN3ME2xMlIxODdzIN88US=> NYrDZpdsW0GQR1XS
ES7 M13vWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHhbGZ5UUN3ME2xMlI4QTVzIN88US=> MWPTRW5ITVJ?
HEL MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFwM{GwNlkh|ryP MknDV2FPT0WU
ES4 MnXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTDb2lKSzVyPUGuN|Q6QThizszN MmO5V2FPT0WU
NCI-SNU-1 M13iTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDDR4k3UUN3ME2xMlM3PTV3IN88US=> MkjsV2FPT0WU
MDA-MB-415 MkjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jubmlEPTB;MT6zPFg2KM7:TR?= M{LsdHNCVkeHUh?=
NCI-H2342 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTFwNECyOlkh|ryP MVnTRW5ITVJ?
NB69 NXLJeo54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTJOnJmUUN3ME2xMlQ3OjdzIN88US=> M2Tt[HNCVkeHUh?=
D-247MG NY\YUmh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;0NGlEPTB;MT61NVEzOiEQvF2= MlLyV2FPT0WU
SCC-4 NWi1ZnNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFwNUm4PFch|ryP MVjTRW5ITVJ?
HuH-7 NFLyWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFwNkeyPVMh|ryP M{LocnNCVkeHUh?=
A388 NGHvdG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTFwNki3NlQh|ryP NVfncYJZW0GQR1XS
Calu-3 NVPFO5BTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHNTWM2OD1zLkewOlk4KM7:TR?= NHrTcohUSU6JRWK=
NCI-H1648 NUnuN2VrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3se4lsUUN3ME2xMlcyPDF6IN88US=> NXe4TXJIW0GQR1XS
NCI-H2052 NHvqbXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnuyTWM2OD1zLkeyNlAyKM7:TR?= M{TmSHNCVkeHUh?=
Ramos-2G6-4C10 NH7KWJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHvbI1KSzVyPUGuO|M3PTZizszN NWSxT|huW0GQR1XS
DEL MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LJSGlEPTB;MT63OFY6OiEQvF2= NH7DdZVUSU6JRWK=
SNU-423 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTFwN{ixOVch|ryP MWTTRW5ITVJ?
COR-L23 M4TYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXu1TVJ4UUN3ME2xMlc6QDd2IN88US=> M2TlT3NCVkeHUh?=
OMC-1 NHPGcVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3qxcWlEPTB;MT64OlAyPiEQvF2= NYr0Vo93W0GQR1XS
EW-11 NHy3UGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7tTWM2OD1zLkm1OlU4KM7:TR?= NYTQPJBvW0GQR1XS
HSC-3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[yNWxKSzVyPUGuPVY{PjVizszN M4ro[HNCVkeHUh?=
MLMA MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe3e3JuUUN3ME2xMlk3Pjd5IN88US=> MVnTRW5ITVJ?
RCM-1 MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nMfGlEPTB;Mj6wNFM6QSEQvF2= M3yyVXNCVkeHUh?=
MFE-280 M1n5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXaTWM2OD1{LkCyPFQ5KM7:TR?= MULTRW5ITVJ?
ES8 M1;JOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnZWIFKSzVyPUKuNlU1PzFizszN NIexUppUSU6JRWK=
TE-11 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\mbY1bUUN3ME2yMlI6PDd|IN88US=> MlvRV2FPT0WU
HuO-3N1 NGXuTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHsW2N{UUN3ME2yMlQ5PzhizszN MmHBV2FPT0WU
MHH-NB-11 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTJwNUGxOVgh|ryP NIPkclRUSU6JRWK=
TGBC11TKB Mn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rkTWlEPTB;Mj61O|Y5OSEQvF2= MX3TRW5ITVJ?
HOP-92 NH23VGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1j0e2lEPTB;Mj61PFc1OyEQvF2= MXTTRW5ITVJ?
IGR-1 NYrPTlE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{S1b2lEPTB;Mj62NlA{PSEQvF2= NFzCZWxUSU6JRWK=
GOTO MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LvSmlEPTB;Mj62OVM4PyEQvF2= M1rtU3NCVkeHUh?=
NCI-H1650 M4PvTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjXTnNKSzVyPUKuO|IzOTVizszN NHHscHZUSU6JRWK=
NCI-H1581 M1X3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmX1TWM2OD1{Lke5OlgyKM7:TR?= MXzTRW5ITVJ?
NCI-H2405 NF;oZ5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2G0W2lEPTB;Mj64Nlc5OiEQvF2= NH3YVmJUSU6JRWK=
U-118-MG Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvv[pA3UUN3ME2yMlk3PDlzIN88US=> Mn[3V2FPT0WU
DoTc2-4510 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTrTWM2OD1|LkCxOFE4KM7:TR?= MYHTRW5ITVJ?
NCI-H596 NHTNeohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTNwMES5PVch|ryP MWnTRW5ITVJ?
MPP-89 Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj1SWc4UUN3ME2zMlA2PjZ4IN88US=> NG\OTXlUSU6JRWK=
GCIY M2rJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[2dGlEPTB;Mz6yNFQ6OSEQvF2= NVu2VY5GW0GQR1XS
SW626 NFvQfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnDflNIUUN3ME2zMlI1PTR|IN88US=> M{KwenNCVkeHUh?=
OCI-AML2 M1TWOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDDPJY6UUN3ME2zMlMyOjd{IN88US=> NEL1e5pUSU6JRWK=
NBsusSR NYj0OnVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnLTWM2OD1|LkO0PVM5KM7:TR?= MmfuV2FPT0WU
AN3-CA MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[wTWM2OD1|LkS0NlM5KM7:TR?= NHXmbJFUSU6JRWK=
EFM-19 NEjPd|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7tbXdEUUN3ME2zMlQ5OzN7IN88US=> M33JWXNCVkeHUh?=
RVH-421 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLBSXlyUUN3ME2zMlU3QDd5IN88US=> Mly0V2FPT0WU
5637 NYr3U2xrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jZfmlEPTB;Mz62NVExOyEQvF2= NHnTSpJUSU6JRWK=
PANC-08-13 NID0RXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTNwNkO0O|Ih|ryP MmPvV2FPT0WU
H9 NWLwcXExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTXXoZKSzVyPUOuOlcyPDRizszN NH:0N4xUSU6JRWK=
KARPAS-299 NH\3[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\RVIFWUUN3ME2zMlY4OzZzIN88US=> NUTFOXJDW0GQR1XS
TE-5 M2ewdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTNwN{C3NFkh|ryP Mn;QV2FPT0WU
NOS-1 Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTNwN{m4N|Qh|ryP NYXMdnlMW0GQR1XS
HH NVvBb3RjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnWNGRKSzVyPUOuPFM5PjhizszN MUTTRW5ITVJ?
769-P MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfwdGhKSzVyPUOuPFk2OSEQvF2= MUjTRW5ITVJ?
CHP-212 NEPlTGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHSVml[UUN3ME2zMlkzPTR7IN88US=> MmrRV2FPT0WU
NCI-H82 M3XO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnMcmdKSzVyPUOuPVU6OzZizszN MXrTRW5ITVJ?
Mo-T NFHsXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLKdXFLUUN3ME20MlA1OzF{IN88US=> M33HSHNCVkeHUh?=
BB65-RCC NXu1b2o4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTRwMESzPVkh|ryP NHTKN4VUSU6JRWK=
SW1990 NVG0V|V6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrpbIJKSzVyPUSuNFU6ODhizszN MXfTRW5ITVJ?
LK-2 NXvVcJE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTRwMUGyPVMh|ryP M2DlWXNCVkeHUh?=
ES5 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfZc2hKSzVyPUSuNVM6QDVizszN NXrnVmNoW0GQR1XS
JVM-3 NEXOTIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3IbnBXUUN3ME20MlE5OjJ{IN88US=> MVTTRW5ITVJ?
RPMI-7951 NFPKVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PhXGlEPTB;ND6yNlQyOyEQvF2= Mkf4V2FPT0WU
Calu-6 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LtdGlEPTB;ND6yO|g5OSEQvF2= M4jYUHNCVkeHUh?=
LC-2-ad MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzITWM2OD12LkK5OVY5KM7:TR?= NGnJSnlUSU6JRWK=
SW954 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;tTWM2OD12LkK5OlYh|ryP MUXTRW5ITVJ?
H-EMC-SS MlvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTRwM{G4N|Eh|ryP NFXifoxUSU6JRWK=
ES3 Mnq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3PXpdKSzVyPUSuN|U1PDFizszN NWe0NlE2W0GQR1XS
no-11 NEP4bpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPSTWM2OD12LkO1OVU1KM7:TR?= MnzWV2FPT0WU
LAN-6 MmHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXlZm9NUUN3ME20MlQ2OTh7IN88US=> NYG1dmFbW0GQR1XS
FTC-133 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jRSGlEPTB;ND61N|k2KM7:TR?= MULTRW5ITVJ?
8505C NH\jPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTRwNUSyN{DPxE1? MlviV2FPT0WU
SW620 NV;P[mdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\RTWM2OD12LkW3NFU4KM7:TR?= M4i3dXNCVkeHUh?=
BCPAP NFzKTFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUL5VodbUUN3ME20MlY{PDhzIN88US=> NWjl[GFEW0GQR1XS
SK-LU-1 NYTIdG5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrrTWM2OD12Lk[2NFg6KM7:TR?= NFLhUVdUSU6JRWK=
NCI-H1623 MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInobHRKSzVyPUSuO|AzOjhizszN M1vibnNCVkeHUh?=
C2BBe1 NUj3e4pYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzYWHE6UUN3ME20Mlc1ODB6IN88US=> M3nKXHNCVkeHUh?=
GP5d MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XWNWlEPTB;ND63PFM5QCEQvF2= MXfTRW5ITVJ?
NB6 M{LMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPMTWM2OD12Lki2NlA1KM7:TR?= NXXZcWRuW0GQR1XS
MDA-MB-157 MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X2UmlEPTB;ND64PFc3KM7:TR?= M2Dve3NCVkeHUh?=
UMC-11 NV3DNGpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rGdmlEPTB;ND64PFk3PCEQvF2= NWfvb2JUW0GQR1XS
HCC1419 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TxO2lEPTB;ND65NFA3OyEQvF2= NYfZTIsxW0GQR1XS
NCI-H2029 Mk\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nGVmlEPTB;ND65OFE5PSEQvF2= M1W1WnNCVkeHUh?=
LXF-289 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHmSlRoUUN3ME21MlA{PzF7IN88US=> M4DnSHNCVkeHUh?=
KINGS-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTVwMEe3OFQh|ryP NHjYWG9USU6JRWK=
HD-MY-Z MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vXWmlEPTB;NT6yN|k3QSEQvF2= NHHqTYZUSU6JRWK=
ESS-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPWN246UUN3ME21MlI2PTl5IN88US=> MmHKV2FPT0WU
GI-1 NFG2dYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjreoRKSzVyPUWuNlc6OjZizszN NEf3O5FUSU6JRWK=
RPMI-2650 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrxeJRKSzVyPUWuN|YyPiEQvF2= NFzkUW9USU6JRWK=
IA-LM NX\MdXc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvTNYhTUUN3ME21MlM6QDdzIN88US=> NXjXU5l1W0GQR1XS
KP-4 Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHMOXppUUN3ME21MlQ3OzN2IN88US=> NYfDbJdFW0GQR1XS
G-402 M4rWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonHTWM2OD13LkWxPFY2KM7:TR?= MY\TRW5ITVJ?
OS-RC-2 MkmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;pTWM2OD13LkWyOlA1KM7:TR?= MmjVV2FPT0WU
NCI-H1155 M3jPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDkUWtwUUN3ME21MlU1QTV3IN88US=> NVfMW3JMW0GQR1XS
OE19 M4rLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjaU3BXUUN3ME21MlY5PjJ2IN88US=> M3n6V3NCVkeHUh?=
U-2-OS M2XJXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzxZ5JKSzVyPUWuPFkxOTNizszN NGO0O3RUSU6JRWK=
SCC-15 NIj5UoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTVwOUO2OlIh|ryP M{XDZ3NCVkeHUh?=
NCI-H630 NFm5cldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TZdmlEPTB;NT65PVQxPCEQvF2= NVixTZlLW0GQR1XS
PFSK-1 NH[4S|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTZwMEWyOVkh|ryP NX\NbZM5W0GQR1XS
NCI-H1770 M2ni[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjxfm5KSzVyPU[uNlA5PzRizszN MXzTRW5ITVJ?
SK-MEL-3 NIjZSZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnaTWM2OD14LkSyPVE2KM7:TR?= MnrGV2FPT0WU
LB1047-RCC NWDacGdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTZwNEe2NlUh|ryP MUnTRW5ITVJ?
NCI-H446 M1Hl[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTycWhCUUN3ME22MlYzQTJ3IN88US=> NF7sWZFUSU6JRWK=
SW780 NEXK[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHGyZ2xKSzVyPU[uO|AyQDVizszN NX7EPIYxW0GQR1XS
NEC8 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUe2fGtOUUN3ME22Mlc3PjNizszN NYLvcY9NW0GQR1XS
NOMO-1 M2T5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTZwN{ixNVEh|ryP NHTlXFBUSU6JRWK=
COLO-668 NYraSZh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTZwOESzPFch|ryP NEfpXJFUSU6JRWK=
MC116 M2\h[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\LTWM2OD14LkmzPFk4KM7:TR?= MVLTRW5ITVJ?
HCC1937 M4LrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\oOlJKSzVyPU[uPVkzPTFizszN NH30ZlFUSU6JRWK=
NCI-N87 Mom0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof4TWM2OD15LkG5Nlk{KM7:TR?= MUfTRW5ITVJ?
COLO-320-HSR MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fUPWlEPTB;Nz6yNlc{QCEQvF2= NFr6RnhUSU6JRWK=
HCC1806 M1HxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M122SGlEPTB;Nz6yOlA1PCEQvF2= NHLJ[nBUSU6JRWK=
OVCAR-3 M1WzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7IbVBKSzVyPUeuN|MxOzhizszN M4PCd3NCVkeHUh?=
NUGC-3 M3;oWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HmU2lEPTB;Nz6zPVY6PCEQvF2= NXzFUG1sW0GQR1XS
SW1783 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzkTWM2OD15LkSzNVc2KM7:TR?= MkLMV2FPT0WU
GCT MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTdwNU[5NFYh|ryP NW\k[pdDW0GQR1XS
NCI-H2126 NXzROoJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYKz[5ZsUUN3ME23Mlc{PjJ3IN88US=> NW[3RoJrW0GQR1XS
MEL-HO NVjUU|d{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjGRY5KSzVyPUeuO|cxPTRizszN NIrjdI9USU6JRWK=
CAPAN-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTmTWM2OD15Lke3N|U4KM7:TR?= M1naeXNCVkeHUh?=
SW756 M{m2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfzd|lKSzVyPUeuO|g{OzNizszN MljLV2FPT0WU
SKG-IIIa NYKyd4IzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzDfodtUUN3ME23MlgyQDl{IN88US=> MVfTRW5ITVJ?
HCE-T M{LYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTdwOEe3PFMh|ryP MmLTV2FPT0WU
Ca-Ski M37BNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTdwOUmzPFMh|ryP MWPTRW5ITVJ?
COLO-684 NWn4eYRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrQNmJpUUN3ME24MlAyQDF6IN88US=> MmjRV2FPT0WU
KYSE-70 NHnWWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTJTWM2OD16LkC3O|I6KM7:TR?= M2rRenNCVkeHUh?=
TI-73 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLVN4lKUUN3ME24MlI2QDVzIN88US=> MYXTRW5ITVJ?
BT-20 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\jfmlEPTB;OD6yOlA2OiEQvF2= MXrTRW5ITVJ?
MHH-ES-1 MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDhUVRKUUN3ME24MlUyQDN2IN88US=> NVHXUFVrW0GQR1XS
TE-12 NEf2UmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn65TWM2OD16LkW5PVMyKM7:TR?= Moe5V2FPT0WU
YH-13 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jD[GlEPTB;OD62NVAxQCEQvF2= Mn;FV2FPT0WU
SF126 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Hkb2lEPTB;OD64N|g3PSEQvF2= M2r4PXNCVkeHUh?=
J82 NX7uN3lxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRThwOUCwN|gh|ryP MVHTRW5ITVJ?
RCC10RGB M{jJUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRThwOUm1OlEh|ryP MnnrV2FPT0WU
SK-UT-1 MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ftZmlEPTB;OT6wOFk1PSEQvF2= M1W1VXNCVkeHUh?=
LB2241-RCC MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnX2TWM2OD17LkG5NVM4KM7:TR?= MYHTRW5ITVJ?
LB996-RCC M2m5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHTbYlCUUN3ME25MlE6QDlizszN MXfTRW5ITVJ?
EPLC-272H MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{L5d2lEPTB;OT6zO|Y2PyEQvF2= MYfTRW5ITVJ?
CTV-1 NX\jWGZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\FXVBjUUN3ME25MlU3PTN{IN88US=> NFXUUpFUSU6JRWK=
HSC-2 MmnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zkNGlEPTB;OT61O|U2KM7:TR?= M2LBXHNCVkeHUh?=
SK-MEL-28 NFPzUFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{CzNmlEPTB;OT62NVg6OyEQvF2= M2\wN3NCVkeHUh?=
MMAC-SF NXvmWJBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jHbGlEPTB;OT62PFc2KM7:TR?= MmnhV2FPT0WU
CP50-MEL-B NH\IRXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LpeGlEPTB;OT63OVc5OiEQvF2= NFTlXVhUSU6JRWK=
HT-1080 NWHPVlF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jOS2lEPTB;OT63O|c{QSEQvF2= NGTMV|hUSU6JRWK=
HEC-1 NEPWbW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTFyLkOzOVIh|ryP MlroV2FPT0WU
AGS NY\VT5FmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnv[W5KSzVyPUGwMlM4PCEQvF2= NIjEWWtUSU6JRWK=
GAMG M3jhfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTFyLkWxOlIh|ryP NITPN3lUSU6JRWK=
SW48 NU\1XZBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnzZ3hKSzVyPUGwMlUyQDlizszN MnXvV2FPT0WU
U031 Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFyLkW5NFgh|ryP M3LuNHNCVkeHUh?=
OVCAR-5 NYraSIg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfQTWM2OD1zMD62OFI6KM7:TR?= NHH4VXNUSU6JRWK=
SF295 NV;XTI9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknKTWM2OD1zMD62O|A1KM7:TR?= MU\TRW5ITVJ?
BHT-101 M3nnZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zqd2lEPTB;MUCuO|E4PyEQvF2= MkHCV2FPT0WU
VMRC-RCZ MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoWwTWM2OD1zMT6zNlAyKM7:TR?= Moe4V2FPT0WU
ACHN M1zYXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTFzLkSyNVEh|ryP NHS2TYpUSU6JRWK=
NCI-H526 NEDVWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlH0TWM2OD1zMT61NFQ{KM7:TR?= M1nSZ3NCVkeHUh?=
MN-60 M4nBXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTFzLkWzPUDPxE1? M2\RT3NCVkeHUh?=
NCI-H2291 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTFzLkW0OlYh|ryP MVXTRW5ITVJ?
SCC-25 M1PaUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTFzLke1OVYh|ryP MlLPV2FPT0WU
SK-MEL-2 M4\xSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHn[YZKSzVyPUGxMlc3OzdizszN M1fBcnNCVkeHUh?=
SN12C MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrZTWM2OD1zMT65N|U2KM7:TR?= MXPTRW5ITVJ?
NCI-H69 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{K2WWlEPTB;MUKuOFI{PCEQvF2= MlzRV2FPT0WU
ME-180 NIjuVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTF{LkewOVQh|ryP Mln4V2FPT0WU
MC-IXC M{\Kemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;TcWZKSzVyPUGyMlc2OThizszN Ml[3V2FPT0WU
NCI-H2347 MnPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEH2XI5KSzVyPUGyMlc3OTRizszN Mn7GV2FPT0WU
M059J NGXyfXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnr4TWM2OD1zMj63O|I4KM7:TR?= Ml;NV2FPT0WU
A2058 NYrTTWpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTF{Lki2PFEh|ryP M3LZ[HNCVkeHUh?=
VA-ES-BJ NWXnfY9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlW2TWM2OD1zMj64O|g2KM7:TR?= M4r2TXNCVkeHUh?=
Ca9-22 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPvUoJKSzVyPUGyMlk1PTFizszN M{HmZnNCVkeHUh?=
KNS-42 NVLSWVNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTF{Lkm5PFQh|ryP M4\CVHNCVkeHUh?=
LoVo NEfSToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXhd2F3UUN3ME2xN{4zOzF|IN88US=> NFTVRWhUSU6JRWK=
AM-38 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTF|LkK1OlYh|ryP MYDTRW5ITVJ?
NB5 MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mki1TWM2OD1zMz6zO|UzKM7:TR?= NGjpeHhUSU6JRWK=
L-363 NXLiTVNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTF|LkSwN|Mh|ryP NXK5[FJ5W0GQR1XS
SK-MEL-30 M3LuTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXJXZNZUUN3ME2xOE4xPjR3IN88US=> M1\H[HNCVkeHUh?=
NCI-H1563 NXvBb|ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LVPWlEPTB;MUSuOlA{QSEQvF2= MlrpV2FPT0WU
NCI-H2228 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\TdGV6UUN3ME2xOE43ODd5IN88US=> MUHTRW5ITVJ?
MFM-223 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\VcGlEPTB;MUWuNVgyOyEQvF2= MVjTRW5ITVJ?
LB831-BLC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XGfGlEPTB;MUWuNlc3PyEQvF2= M{izUXNCVkeHUh?=
SW872 MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nXZ2lEPTB;MUWuN|A5PiEQvF2= Mo\IV2FPT0WU
NCI-H522 MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTF3LkOzNFYh|ryP MnHNV2FPT0WU
EW-1 MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInoeXNKSzVyPUG1MlU1PjJizszN NV7mbZZYW0GQR1XS
HN MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr3VlJ5UUN3ME2xOU42QTR{IN88US=> M2LXbHNCVkeHUh?=
SW837 M{HXbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTF3Lke4OFch|ryP NHL6OVVUSU6JRWK=
SCC-9 NWXrb4pUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTF3LkixNVQh|ryP MlHMV2FPT0WU
MKN7 NE\1TIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTF3Lkm3N|Ih|ryP NIrVemlUSU6JRWK=
KYSE-410 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUD3PYxOUUN3ME2xOk42QTFizszN NF3i[2hUSU6JRWK=
SK-N-DZ MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmOyTWM2OD1zNj62NVE3KM7:TR?= MVPTRW5ITVJ?
COR-L105 MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrnTWM2OD1zNj62OVI5KM7:TR?= Mm\rV2FPT0WU
LB2518-MEL MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTF4LkizPFkh|ryP NWnHWpM{W0GQR1XS
OVCAR-4 M2Gycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTF4Lki4OlIh|ryP NWO1fIN2W0GQR1XS
TK10 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTWSm41UUN3ME2xOk46PDd|IN88US=> M1HrW3NCVkeHUh?=
KNS-62 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTF4Lkm3O|ch|ryP NIPYO3RUSU6JRWK=
RPMI-8866 NUXtOYVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P4[WlEPTB;MUeuNVc{OiEQvF2= MWLTRW5ITVJ?
HuP-T4 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1W2fGlEPTB;MUeuNlQ6PSEQvF2= M37tWXNCVkeHUh?=
CGTH-W-1 NGPpNXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTBbmVKSzVyPUG3MlUzOTlizszN NV7u[IJNW0GQR1XS
T-24 M2nEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\hTWM2OD1zNz61N|Q4KM7:TR?= MmfWV2FPT0WU
HT-3 NGru[INIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTF5LkW5NVQh|ryP NVHy[|VMW0GQR1XS
KS-1 NGjPVnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LPd2lEPTB;MUeuOlc{KM7:TR?= NVzsfJoyW0GQR1XS
NCI-H1792 NXiyU4htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTF5Lke5PEDPxE1? MYPTRW5ITVJ?
ABC-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfXXZRkUUN3ME2xO{45OTRzIN88US=> NEK4NFlUSU6JRWK=
BPH-1 Mn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGG1b2JKSzVyPUG4MlE3QDVizszN NH\Fe5pUSU6JRWK=
A431 M3WxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTF6LkSxNlch|ryP NW\3bJlpW0GQR1XS
T98G MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvPeHRXUUN3ME2xPE42OTV5IN88US=> NE\hd2dUSU6JRWK=
BHY NFuzZYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4S3dGlEPTB;MUiuPFY6KM7:TR?= MVXTRW5ITVJ?
Capan-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIj5TYJKSzVyPUG4MlkxPzhizszN M4DDb3NCVkeHUh?=
MDA-MB-175-VII MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXvdpBKSzVyPUG4MlkzODlizszN NGP1V2VUSU6JRWK=
CAL-27 NVjIN29oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;1ZmlEPTB;MUmuNFQ5PyEQvF2= M4LXTXNCVkeHUh?=
AsPC-1 NEPYOmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnkfGpXUUN3ME2xPU45PjV5IN88US=> NFPzbo1USU6JRWK=
KU812 MlrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTF7Lkm1O|Mh|ryP NF63[VVUSU6JRWK=
NCI-H441 NIDnSI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Twb2lEPTB;MkCuNFAyKM7:TR?= NHrOfVZUSU6JRWK=
Mewo Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jySmlEPTB;MkCuNVI5QCEQvF2= NX\TUpZHW0GQR1XS
SK-MEL-24 NXnjNIxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f6VmlEPTB;MkCuNVQ4PyEQvF2= Mlj4V2FPT0WU
NCI-H727 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJyLkK3NFQh|ryP M1TZeHNCVkeHUh?=
EKVX MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnThTWM2OD1{MD62NFYh|ryP MXnTRW5ITVJ?
RT-112 NGf2O3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK3RWtTUUN3ME2yNE43OTJ{IN88US=> NHPMSJdUSU6JRWK=
CAMA-1 M{joZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTJyLkm4NFMh|ryP MkKzV2FPT0WU
SW900 M1rCW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTJzLkCxOFkh|ryP NHi4TWpUSU6JRWK=
NCI-H23 NYrQTopnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPYNXVKSzVyPUKxMlEzPzdizszN MU\TRW5ITVJ?
SK-PN-DW MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvWTWM2OD1{MT6xOlQ6KM7:TR?= NF3WRlJUSU6JRWK=
BB30-HNC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[2XGlEPTB;MkGuNlc1PSEQvF2= MmnQV2FPT0WU
VM-CUB-1 NUHXT3VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHnTWM2OD1{MT6zOVM3KM7:TR?= M3W4VXNCVkeHUh?=
IST-MEL1 MkHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUm3SoVvUUN3ME2yNU4{Pjl{IN88US=> M4LZN3NCVkeHUh?=
CTB-1 NXjSbmwzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTJzLkS3OVUh|ryP MoDDV2FPT0WU
LCLC-103H NIPOWIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTvTWM2OD1{Mj6xOVgzKM7:TR?= M1LFUXNCVkeHUh?=
PANC-03-27 NXK0e2llT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTJ{LkWxOlkh|ryP NW\uXlhuW0GQR1XS
HTC-C3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfDbpZKSzVyPUKyMlU2PTVizszN NXjQOVRnW0GQR1XS
TE-8 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnSVohKSzVyPUKzMlI2PjVizszN MnfQV2FPT0WU
NCI-H292 NULOOXFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL6NYVKSzVyPUK1MlM2OzZizszN MX3TRW5ITVJ?
COLO-680N M4SzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zPb2lEPTB;MkWuOlMzQSEQvF2= NVfOcYNxW0GQR1XS
KYSE-520 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJ3Lk[0OEDPxE1? NVGweXFSW0GQR1XS
NB10 M130WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XRW2lEPTB;Mk[uN|EyPyEQvF2= Mne3V2FPT0WU
NCI-H661 M37KVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJ4LkS3NVMh|ryP NUeybYxQW0GQR1XS
GMS-10 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfTc4dKSzVyPUK2Mlg3OzhizszN MXLTRW5ITVJ?
NCI-H2122 NUL4NXV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkGxTWM2OD1{Nj65PVk5KM7:TR?= M1LSRXNCVkeHUh?=
OVCAR-8 NXH2[XJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjaOmZzUUN3ME2yO{4xPjN6IN88US=> MWfTRW5ITVJ?
DJM-1 NUfSTVFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrpTWM2OD1{Nz6xOFU1KM7:TR?= MofRV2FPT0WU
UACC-893 NITpN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTwWVJ[UUN3ME2yO{46QDd6IN88US=> M2OyWHNCVkeHUh?=
C8166 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJ6Lk[5N|gh|ryP MWHTRW5ITVJ?
NCI-H1693 MknRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13vcGlEPTB;MkiuOlk4PSEQvF2= M1H6SXNCVkeHUh?=
TYK-nu M{WyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHlTWM2OD1|MD6wN|Q2KM7:TR?= NVPOR4p{W0GQR1XS
SW1710 MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4m3SGlEPTB;M{CuNVI3KM7:TR?= NITX[W9USU6JRWK=
A375 NEnKSmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTNyLkOyOFMh|ryP MWPTRW5ITVJ?
HMV-II NF31W|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fsOmlEPTB;M{GuN|U6OiEQvF2= NXzzVnRmW0GQR1XS
NCI-H2087 NF\2UlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;EdW94UUN3ME2zNU43OzV{IN88US=> Mm\sV2FPT0WU
CAL-54 NYfpZnV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\lTWM2OD1|MT63NlQyKM7:TR?= MYrTRW5ITVJ?
HCC70 NWPiboUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTnTWM2OD1|Mj6xN|g4KM7:TR?= M4TBO3NCVkeHUh?=
ES1 NHLMZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvD[4xWUUN3ME2zNk4{ODZ{IN88US=> MkWzV2FPT0WU
NCI-H1355 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTJTWM2OD1|Mz6yNFQh|ryP MU\TRW5ITVJ?
CFPAC-1 NHvrcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIe1bodKSzVyPUOzMlI{OzJizszN M3LI[XNCVkeHUh?=
MKN28 MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTN|LkO4NFkh|ryP NInzenBUSU6JRWK=
HDLM-2 NF61S|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTN|Lk[5N|Eh|ryP MnHTV2FPT0WU
PANC-10-05 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PtcWlEPTB;M{SuNVAyPCEQvF2= M3fLSXNCVkeHUh?=
SAS NFP1dWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DwfGlEPTB;M{SuOFU3PSEQvF2= M2HPcXNCVkeHUh?=
HCC1395 M4jDbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ryV2lEPTB;M{SuO|E5PiEQvF2= M{WwSXNCVkeHUh?=
8305C NHixPXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTN3Lki0NVUh|ryP MUTTRW5ITVJ?
KM12 M3nXRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnv1TWM2OD1|Nj63OVQ4KM7:TR?= NGPhUllUSU6JRWK=
SW1116 M336TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTN5LkW5PVIh|ryP NWfoVFBJW0GQR1XS
SK-MEL-1 NIXVZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HUNWlEPTB;M{iuN|M5QSEQvF2= MnrOV2FPT0WU
HCC2218 M1rUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnv6TWM2OD1|OD62OVE6KM7:TR?= NWDoRYZuW0GQR1XS
T84 MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXrTWM2OD1|OD63OFA6KM7:TR?= MnHsV2FPT0WU
ETK-1 M17L[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTN7LkCyNkDPxE1? M3rKeXNCVkeHUh?=
COLO-800 NGfQNmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jvUWlEPTB;M{muN|g3QCEQvF2= MUnTRW5ITVJ?
CAL-12T M1LsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3u3WGlEPTB;M{muOVI5OSEQvF2= NImxNFJUSU6JRWK=
ACN MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTRyLkS5NVEh|ryP NUT4SW5NW0GQR1XS
SJSA-1 NE\B[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVr2foZMUUN3ME20NU4yPTl4IN88US=> Mn7sV2FPT0WU
PSN1 NHfTOIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTRzLkG3OFkh|ryP Ml\1V2FPT0WU
D-566MG NITMTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTRzLkKwPFYh|ryP MnPrV2FPT0WU
EGI-1 M{C2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fuSWlEPTB;NEKuOFI5KM7:TR?= MYLTRW5ITVJ?
A204 M1jhc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIP0bplKSzVyPUSyMlY{QDhizszN M{TPcXNCVkeHUh?=
Saos-2 M2\Demdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUn0bI1nUUN3ME20Nk45OzZ7IN88US=> NVjMNo05W0GQR1XS
SNU-C2B NIq2PW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPk[XFMUUN3ME20N{43QDd6IN88US=> Mn\wV2FPT0WU
HLE MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTR2LkC4OVYh|ryP M2rBVXNCVkeHUh?=
SW1463 M2\lXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorxTWM2OD12ND65PVcyKM7:TR?= NH[1N4pUSU6JRWK=
DSH1 MlrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTR3LkCwN|Mh|ryP MmDmV2FPT0WU
MCF7 MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LScGlEPTB;NEWuOVA2OSEQvF2= MlvnV2FPT0WU
K5 NVfBTIdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nFb2lEPTB;NEWuPVQxPSEQvF2= MYLTRW5ITVJ?
NCI-H358 NHLlXlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXMdWRKSzVyPUS3MlIyPSEQvF2= MWHTRW5ITVJ?
NCI-H2030 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi0SoJKSzVyPUS3MlI{PzRizszN M134enNCVkeHUh?=
SW948 NXXWNnpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfGToljUUN3ME20O{41PjRizszN NULCVo5HW0GQR1XS
BALL-1 M4fsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nLOWlEPTB;NEeuOlE3QCEQvF2= M2f0[3NCVkeHUh?=
TE-9 NV7z[XIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoCwTWM2OD12Nz65OVgyKM7:TR?= Mmf0V2FPT0WU
SK-N-FI M1T4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXCdVVKSzVyPUS4MlA{PThizszN MWDTRW5ITVJ?
KALS-1 M3XlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTR6LkGyPFkh|ryP Mlj2V2FPT0WU
HO-1-N-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfGOnpKUUN3ME20PE44PDR3IN88US=> NUPvPYVpW0GQR1XS
NCI-H2452 MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLwTWM2OD12OT6xNVUzKM7:TR?= MULTRW5ITVJ?
OC-314 MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3W2U2lEPTB;NEmuOlg{PCEQvF2= M1vCbnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03366103 Recruiting Metastatic Malignant Solid Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Small Cell Lung Carcinoma|Stage III Small Cell Lung Carcinoma AJCC v7|Stage IIIA Small Cell Lung Carcinoma AJCC v7|Stage IIIB Small Cell Lung Carcinoma AJCC v7|Stage IV Small Cell Lung Carcinoma AJCC v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 29 2017 Phase 1|Phase 2
NCT03181126 Recruiting Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma AbbVie November 28 2017 Phase 1
NCT03222609 Recruiting Myelofibrosis (MF) AbbVie October 31 2017 Phase 2
NCT02520778 Recruiting EGFR Activating Mutation|EGFR Exon 19 Deletion Mutation|EGFR NP_005219.2:p.G719X|EGFR NP_005219.2:p.L858R|EGFR NP_005219.2:p.L861Q|EGFR NP_005219.2:p.T790M|Stage III Non-Small Cell Lung Cancer AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Non-Small Cell Lung Cancer AJCC v7 National Cancer Institute (NCI) March 31 2016 Phase 1
NCT02591095 Active not recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Cirrhosis|Hepatitis B Infection|Hepatitis C Infection|Metastatic Malignant Solid Neoplasm|Recurrent Hepatocellular Carcinoma|Recurrent Malignant Solid Neoplasm|Refractory Malignant Neoplasm|Stage IV Hepatocellular Carcinoma AJCC v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 7 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • Answer:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • Question 2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Tags: buy Navitoclax (ABT-263) | Navitoclax (ABT-263) supplier | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | Navitoclax (ABT-263) manufacturer | order Navitoclax (ABT-263) | Navitoclax (ABT-263) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID